A review published in the Annals of Internal Medicine outlines the 2019 ADA guidelines for self-monitoring of blood glucose and the use of continuous glucose monitors and automated insulin delivery systems.
Years before the first closed-loop insulin delivery system was approved, patients with diabetes had already been implementing the technology into their own care.
Few smartphone apps for self-management of type 2 diabetes provide sufficient real-time action prompts or education on blood glucose monitoring.
Investigators evaluate the performance of the G6 factory-calibrated continuous glucose monitoring system over 10 days.
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
Researchers conducted a randomized, open-label trial to assess the effect of an automated closed-loop insulin delivery system on glycemic control in hospitalized patients.
Patients were randomly assigned to receive insulin aspart or Technosphere inhaled insulin.
In children with type 1 diabetes, the Omnipod hybrid closed-loop personal model system was safe and performed well.
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
Participants completed surveys for fear of hypoglycemia, hypoglycemia unawareness, and problem areas in diabetes questionnaire.
The safety assessment included incidence of insertion or procedure-related removal and device-related serious adverse events through 180 after insertion.